Cochrane Summaries

Trusted evidence. Informed decisions. Better health.

Cerebrolysin for vascular dementia

Chen N, Yang M, Guo J, Zhou M, Zhu C, He L
Published Online: 
31 January 2013

Vascular dementia (VaD) is a common disorder which currently lacks definitive treatments. Cerebrolysin, a peptide preparation produced from purified pig brain proteins, seems to be a promising intervention based on animal studies and clinical trials in other conditions. We identified six trials involving 597 participants suitable for inclusion in this review. Pooled results showed improvements in cognitive function and global function in patients with VaD of mild to moderate severity, with no obvious side effects related to Cerebrolysin. However, due to the limited number of included trials, varying treatment durations and short-term follow-up, there is insufficient evidence to recommend Cerebrolysin as a routine treatment for patients with VaD.

This record should be cited as: 
Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD008900. DOI: 10.1002/14651858.CD008900.pub2
Assessed as up to date: 
4 November 2012